PharmAbcine to Present at AACR Annual Meeting 2021

DAEJEON,South Korea,March 11,2021 -- PharmAbcine Inc. (KOSDAQ: 208340ks),a clinical-stage biotech company focusing on the development of antibody therapeutics,announced today an e-poster presentation featuring nonclinical data of PMC-309 at American Association for Cancer Research (AACR) Annual Meeting. The meeting will take place virtually over April 10-15 and May 17-21 2021.

Presentation Details

Title:PMC309,a highly selective anti-VISTA antibody enhances T cell activation through blocking the interaction of T cells and myeloid derived suppressor cells (MDSC)

Session category/title: Immunology/Immune Checkpoints

Abstract number: 1116

Poster number: 1626

Presentation Type: E-poster with audio presentation

Date:April 10,2021

PMC-309 is a novel monoclonal IgG (Immunoglobulin G) targeting human VISTA (V-domain Ig Suppressor of T cell Activation) expressed primarily on MDSC (Myeloid-Derived Suppressor Cells). PMC-309 isone of the company's first in classimmuno-oncology drug candidates. It can provide a promising immunotherapeutic strategy through the inhibition of VISTA-positive immunosuppressive cell activities.

"We are delighted to share the data that validate PMC-309's unique mode of action and its therapeutic effect in the preclinical setting," saidDr.Jin-San Yoo,CEO of PharmAbcine. "We find the data highly encouraging,and this will give us added confidence in preparing PMC-309 for global Phase I trial in 2022."

An abstract of the e-poster is currently available at https://www.aacr.org/meeting/aacr-annual-meeting-2021/program/,and the final version of the e-poster will be available at the AACR website on April 10.

About PharmAbcine Inc.

PharmAbcine is a clinical-stage biotech company focusing on the development of fully human antibody therapeutics to treat neovascular disorders,tumors,and other medically unmet diseases. It provides therapeutic antibodies for a wide spectrum of indications from oncology,immuno-oncology,ophthalmology,to respiratory.

PharmAbcine has its own HuPhage library and innovative selection system. PharmAbcine's advanced 3G expression system accommodates high levels of antibody production and steady reproducibility. With these cutting-edge technology platforms,it provides state of the art antibody generation services.

For additional information about PharmAbcine,visit http://www.pharmabcine.comor follow us on Youtubeand Linkedin.

View original content to download multimedia:/news-releases/pharmabcine-to-present-at-aacr-annual-meeting-2021-301245224.html